Breast Cancer Monoclonal Antibodies Market by End-user, Type and Geography - Forecast And Analysis 2023-2027

Breast Cancer Monoclonal Antibodies Market Analysis Report 2023-2027:

The global breast cancer monoclonal antibodies market size is estimated to grow by USD 15 billion at a CAGR of 12.5% between 2022 and 2027. 

The increased number of patient support initiatives for breast cancer awareness is to address the economic and emotional burden associated with breast cancer. Pharmaceutical manufacturers, governments, non-profits, and healthcare providers are striving to improve patient access to resources and close significant healthcare gaps. The Novartis Solutions (STEP) Program for Empowering Patients supports non-profit organizations that provide innovative solutions to the metastatic breast cancer community. Moreover, government organizations such as the Centers for Disease Control and Prevention (CDC) in the US are increasingly offering support to people with breast cancer. Susan G. Komen is a US non-profit organization that partnered with CancerCare to create the Komen Treatment Assistance Program to help cancer patients to overcome financial hardships. Hence, the increasing number of patient support and education programs for breast cancer is expected to drive the growth of the breast cancer monoclonal antibodies market during the forecast period. 

Technavio has segmented the market into End-user, Type, and Geography segments.

• The End-user segment is classified into hospitals, research institutes, and others
• Type segment is classified into humanized, human, chimeric, and murine
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. 

What will be the Size of the Breast Cancer Monoclonal Antibodies Market During the Forecast Period?

To learn more about this report, Request Free Sample

Breast Cancer Monoclonal Antibodies Market Segmentation by End-user, Type, and Geography Analysis

End-user Analysis

Hospitals

The market share growth by the hospital segment will be significant during the forecast period. Hospitals play an important role in the diagnosis, treatment, and management of breast cancer. Monoclonal antibodies have become an essential part of breast cancer treatment in hospitals owing to their highly targeted mechanism of action and efficacy in combating cancer cells. Hospitals often serve as primary centers for breast cancer diagnosis. Hospitals are offering monoclonal antibody drug therapy directly to patients as part of breast cancer treatment plans.

Get a glance at the market contribution of various segments View a PDF Sample

The hospital segment was valued at USD 5.84 billion in 2017.  The increasing number of cancer hospitals across the globe is also supporting the growth of this segment. In this segment, breast cancer is one of the major diagnosed cancer in women across the globe. Although early diagnosis is used as a preventive approach, the risk of breast cancer remains unchanged. Furthermore, the hospital conducts clinical trials and research activities related to breast cancer monoclonal antibodies. They work with pharmaceutical companies and research organizations to discover new monoclonal antibody therapies, contribute to clinical trials, and advance the development of personalized therapeutic approaches for breast cancer patients. Hence, the rising incidence of breast cancer and growing awareness about the early detection of and personalized treatments for the disease will drive the growth of the segment during the forecast period. 

Type Analysis

Human 

The human segment refers to monoclonal antibodies that are derived from humans or that have been engineered to closely resemble human antibodies. These antibodies are made to have a lower risk of immune reaction and improved efficacy compared to non-human and chimeric antibodies. Prominent vendors in the market offering human-type monoclonal antibodies for breast cancer treatment include Roche, Pfizer, and Novartis. These companies continue to invest in research and development to further improve the efficacy and safety of human monoclonal antibodies for breast cancer patients.  Besides, advancements in antibody engineering techniques have enabled the development of more potent and targeted human-type monoclonal antibodies for the treatment of breast cancer, which is expected to fuel the growth of the human segment of the global breast cancer monoclonal antibodies market during the forecast period.

Humanized

A humanized segment refers to a monoclonal antibody that has been engineered to contain a combination of human and non-human components. These antibodies are designed to retain the binding specificity of non-human antibodies while minimizing the risk of immune response and enhancing therapeutic efficacy. Prominent market players in this segment include Roche, Pfizer, and other pharmaceutical companies. These companies continually invest in R&D to enhance the therapeutic benefits of humanized monoclonal antibodies for breast cancer patients. Hence, increased binding specificity, reduced immunogenicity, and enhanced therapeutic efficacy of humanized monoclonal antibodies are expected to increase their acceptance in the treatment of breast cancer, which will boost the growth of the global breast cancer monoclonal antibodies market through the humanized segment during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Technological advances and the increasing prevalence of breast cancer have raised the demand for monoclonal antibodies in the region. The growing adoption of personalized medicine, the need for early detection of breast cancer, and the development of targeted therapies are the key factors driving the growth of the market in this region. North America boasts a strong healthcare infrastructure, expertise in genomics research, and widespread access to monoclonal antibodies.

Moreover, North America has many established medical facilities with state-of-the-art infrastructure and advanced treatment solutions. Medical facilities in the region focus on targeted therapies to treat various types of cancer, including breast cancer. This has led to the demand for personalized medicine and the development of associated monoclonal antibodies. Hence, these factors combined with the growing incidence of breast cancer, will contribute to the growth of the North American breast cancer monoclonal antibodies market during the forecast period. 

COVID Recovery Analysis

The outbreak of COVID-19 adversely affected all countries in North America, especially the US. However, in 2021, the initiation of large-scale vaccination drives?lifted the lockdown and allowed people to travel outside their homes, thus helping rising the number of people going to diagnostic centers and hospitals. Thus, the resumption of healthcare R&D spurred the demand for monoclonal antibodies for breast cancer in North America. Moreover, advances in genomic technologies, the rising prevalence of breast cancer, the increasing demand for personalized medicine, and the availability of advanced healthcare infrastructure will boost the growth of the market during the forecast period.

Buy Now Full Report and Discover More

Key Breast Cancer Monoclonal Antibodies Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Amgen Inc.: The company offers breast cancer monoclonal antibodies such as KANJINTI.

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Celldex Therapeutics Inc.
• Celltrion Co. Ltd.
• Daiichi Sankyo Co
• Ltd., Eisai Co. Ltd.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• Johnson and Johnson Services Inc.
• MacroGenics Inc.
• Merck KGaA, Novartis AG
• Pfizer Inc.
• Puma Biotechnology Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Breast Cancer Monoclonal Antibodies Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Breast Cancer Monoclonal Antibodies Market Drivers

Increasing demand for minimally invasive therapies for breast cancer treatment is the key factor driving the growth of the market. Minimally invasive therapies, such as targeted monoclonal antibody therapy, are gaining importance owing to their potential to provide effective treatments that are less invasive and have fewer side effects. Unlike traditional chemotherapy or surgery, minimally invasive therapies, including monoclonal antibody therapy, target specific cancer cells or molecules and cause minimal damage to healthy tissue.  This targeted approach not only improves patient outcomes but also the quality of life for breast cancer patients by reducing associated complications and recovery times.

Moreover, Shorter hospital stays, reduced pain and discomfort, and faster recovery are the key factors driving the growth of minimally invasive therapies. Breast cancer patients are mainly seeking these alternatives to traditional treatments that often involve more invasive procedures, longer hospital stays, and extended recovery periods.  Hence, this demand is expected to boost the growth of the global breast cancer monoclonal antibodies market during the forecast period.

Significant Breast Cancer Monoclonal Antibodies Market Trends

The growing number of strategic collaborations is the trend in the global breast cancer monoclonal antibodies market. To develop the best therapies to treat breast cancer, major manufacturers are acquiring therapies from other manufacturers through multi-billion dollar collaborations. For example, in August 2021, Gilead Sciences and Merck (MSD) entered into a clinical trial partnership and supply agreement to evaluate the efficacy of former Trodelby with Keytruda in the treatment of triple-negative breast cancer (TNBC). This combination therapy is being analyzed as first-line therapy for patients with locally advanced or metastatic TNBC. 

Moreover, Eisai Co., Ltd. and Bristol-Myers Squibb also announced in June 2021 that they entered into an exclusive global strategic collaboration agreement to co-develop and co-commercialize MORAb-202, an antibody-drug conjugate (ADC). MORAb-202 is Eisai's first ADC, combining Eisai's proprietary anti-folate receptor alpha (FR) antibody and anti-cancer drug eribulin with an enzymatically cleavable linker. Hence, such collaborations are expected to boost the growth of the breast cancer monoclonal antibodies market during the forecast period.

Major Breast Cancer Monoclonal Antibodies Market Challenges

Side effects and safety concerns associated with breast cancer monoclonal antibody treatment are the challenges that affect the growth of the market. Monoclonal antibody therapy has proven effective in treating breast cancer, but emerging side effects and long-term safety concerns may hamper patient acceptance and market growth. Patients may be reluctant to undergo monoclonal antibody treatment or discontinue treatment because of the burden of these side effects. This may lead to lower patient adherence and consequently limit the market growth potential of breast cancer monoclonal antibodies. 

Furthermore, safety concerns about the long-term use of monoclonal antibodies may also discourage patients and healthcare professionals from using these treatments. These concerns may influence patient decision-making and provider prescribing behavior. Thus, this factor will impede the growth of the global breast cancer monoclonal antibodies market during the forecast period.

Buy Now Full Report and Discover More

Key Breast Cancer Monoclonal Antibodies Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Breast Cancer Monoclonal Antibodies Market Customer Landscape

Segment Overview

The breast cancer monoclonal antibodies market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• End-user Outlook (USD Billion, 2017 - 2027)
  • Hospitals
  • Research institutes
  • Others

• Type Outlook (USD Billion, 2017 - 2027)
  • Humanized
  • Human
  • Chimeric
  • Murine

• Region Outlook (USD Billion, 2017 - 2027)
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World 
    • Brazil 
    • Australia
    • Argentina

Breast Cancer Monoclonal Antibodies Market Scope
Report Coverage	Details
Page number	173
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 12.5%
Market growth 2023-2027	USD 15 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	11.12
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 42%
Key countries	US, Canada, France, The Netherlands, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc., Celltrion Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Johnson and Johnson Services Inc., MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Sanofi, Seagen Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Breast Cancer Monoclonal Antibodies Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the breast cancer monoclonal antibodies market between 2023 and 2027
• Precise estimation of the breast cancer monoclonal antibodies market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of breast cancer monoclonal antibodies market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch